Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JABIL INC.

(JBL)
  Report
Delayed Nyse  -  04:00 2022-09-28 pm EDT
60.12 USD   +4.70%
12:30pJPMorgan Adjusts Jabil Price Target to $80 From $82, Maintains Overweight Rating
MT
11:01aGoldman Sachs Adjusts Price Target on Jabil to $78 From $73 Amid Strong Q4 Results, Keeps Buy Rating
MT
08:03aRaymond James Adjusts Price Target on Jabil to $72 From $80, Reiterates Strong Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DentifySensors Biologics Partners with Jabil Inc. to Manufacture Digital Diagnostic Platform

07/12/2022 | 10:00am EDT

IdentifySensors Biologics has partnered with Jabil Inc. to develop processes for reliable robust manufacturing of portable devices that rapidly detect a wide range of infections at the molecular level with accuracy that is superior to PCR testing. The small portable devices, branded Check4®, consist of two main parts: 1) a multiple-use electronic reader about the size of a cell phone; and 2) single-use test cartridges that detect as many as four separate infections simultaneously. For example, a single cartridge can detect COVID, Influenza A, Influenza B and RSV – all from a single saliva sample.

Results appear in minutes on a user's cell phone, at home or on the go. The Check4® platform represents a technological breakthrough, which electronically identifies sequence-specific genetic material of target pathogens. The electronic test produces a digital signal that is analyzed in the cloud in less than three minutes.

Solid-state, digital selectively deposited electrodes enable almost instantaneous results without laboratory work, chemical reagents or amplification. Businesses, governments and organizations can remotely monitor individual and group test results in real time for employees, customers and visitors with accuracy superior to the current gold-standard PCR test, but at a materially lower cost. The Check4® test is positioned to replace PCR and antigen tests for symptomatic and asymptomatic screening.

The technology was developed by IdentifySensors Biologics in partnership with Purdue University, which helped commercialize the process. The technology and applications are secured through multiple patents.


© S&P Capital IQ 2022
All news about JABIL INC.
12:30pJPMorgan Adjusts Jabil Price Target to $80 From $82, Maintains Overweight Rating
MT
11:01aGoldman Sachs Adjusts Price Target on Jabil to $78 From $73 Amid Strong Q4 Results, Kee..
MT
08:03aRaymond James Adjusts Price Target on Jabil to $72 From $80, Reiterates Strong Buy Rati..
MT
09/27Jabil, Hertz rise; Avidity, Provident Financial fall
AQ
09/27Sector Update: Tech Stocks Fall Ahead of Tuesday Close
MT
09/27Sector Update: Tech Stocks Drifting Lower After Modest Morning Advance
MT
09/27Jabil Offers Upbeat Fiscal 2023 Guidance After Fourth-Quarter Results Top Views
MT
09/27Sector Update: Tech Stocks Edge Higher Premarket Tuesday
MT
09/27Sector Update: Tech
MT
09/27Jabil Reports Higher Q4 Earnings, Revenue; Issues Q1 Guidance
MT
More news
Analyst Recommendations on JABIL INC.
More recommendations
Financials (USD)
Sales 2022 32 147 M - -
Net income 2022 954 M - -
Net Debt 2022 1 338 M - -
P/E ratio 2022 9,12x
Yield 2022 0,55%
Capitalization 8 270 M 8 270 M -
EV / Sales 2022 0,30x
EV / Sales 2023 0,27x
Nbr of Employees 238 000
Free-Float 47,7%
Chart JABIL INC.
Duration : Period :
Jabil Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JABIL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 60,12 $
Average target price 77,24 $
Spread / Average Target 28,5%
EPS Revisions
Managers and Directors
Mark T. Mondello Chairman & Chief Executive Officer
Meheryar K. Dastoor Regional Controller-Asia Pacific
May Yap Chief Information Officer & Senior Vice President
Robert L. Katz Executive VP & General Counsel
Steven A. Raymund Independent Director
Sector and Competitors